Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | NEU2 | Q9Y3R4 | 3/20 | 0.47 |
| ▸ | NEU4 | Q8WWR8 | 2/20 | 0.47 |
| ▸ | NEU3 | Q9UQ49 | 2/20 | 0.47 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.47 |
| ▸ | SELL | P14151 | 1/20 | 0.43 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
| ▸ | MAG | P20916 | 2/20 | 0.42 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sialic Acid SCHEMBL22412 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL12391269 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL22879166 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL20299824 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL23366253 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL804644 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL24274184 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL22279106 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL21067569 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL22943658 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813295-B1 | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity | Theobald Therapeutics LLC (US) | 2023-11-14 | — | — | US | claimed |
| US-20210401863-A1 | TREATMENT AND PREVENTION OF NEISSERIA GONORRHOEAE INFECTION USING CMP-ACTIVATED NONULOSONATE ANALOG COMPOUNDS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2021-12-30 | — | — | US | claimed |
| WO-1999029705-A9 | SIALYL LEWIS X AND SIALYL LEWIS A GLYCOMIMETICS | GLYCOMED INC (US) | 1999-11-11 | — | — | WO | claimed |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | CYTODIGM, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3962491-B1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | UNIV SANTIAGO COMPOSTELA (ES) | 2025-08-06 | — | — | EP | disclosed |
| CN-119950526-A | Compound preparation containing N-acetylneuraminic acid ester derivatives and preparation method and application thereof | 铭畅生物医药南通有限公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-4351520-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | CYTODIGM, INC. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117750946-A | Novel particulate compositions comprising sialic acid binding ligands | 希托迪格姆公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-115420821-B | Click-iG: identification method of multiple types of complete glycopeptides | 北京大学 | 2024-03-01 | — | — | CN | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4225278-A1 | PHARMACEUTICAL COMPOSITION OF SIGLEC-BINDING AGENTS | CYTODIGM, INC. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-1654289-B1 | POLYSIALIC ACID DERIVATIVES | LIPOXEN TECHNOLOGIES LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| CN-101031655-A | Method for improving protein expression by strain engineering | DOW GLOBAL TECHNOLOGIES INC (US) | 2007-09-05 | — | — | CN | disclosed |
| US-20060270830-A1 | Polysialic acid derivatives | OPKO PHARMACEUTICALS, LLC | 2006-11-30 | — | — | US | disclosed |
| EP-1654289-A1 | POLYSIALIC ACID DERIVATIVES | Lipoxen Technologies Limited (GB) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016973-A1 | POLYSIALIC ACID DERIVATIVES | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| CN-1359426-A | neisseria genomic sequences and methods of use thereof | CHIRON CORP (US) | 2002-07-17 | — | — | CN | disclosed |
| EP-0587639-B1 | PHARMACEUTICAL COMPOSITIONS | LIPOXEN LTD (GB) | 2001-08-16 | — | — | EP | disclosed |
| WO-1999029705-A9 | SIALYL LEWIS X AND SIALYL LEWIS A GLYCOMIMETICS | GLYCOMED INC (US) | 1999-11-11 | — | — | WO | disclosed |
| US-5846951-A | Pharmaceutical compositions | THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 1998-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270830-A1 | Polysialic acid derivatives | MPST, SUMO2, SUMO1 | NANP 456/4885L3MBTL1 3313/4885NEU2 19/4885 |
| US-20210401863-A1 | TREATMENT AND PREVENTION OF NEISSERIA GONORRHOEAE INFECTION USING CMP-ACTIVATED NONULOSONATE ANALOG COMPOUNDS | ST3GAL3, B3GNT2, FUT5 | NANP 48/4885L3MBTL1 4790/4885NEU2 71/4885 |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | SIGLEC7, SIGLEC9, CD2 | NANP 221/4885L3MBTL1 4101/4885NEU2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.